All News

The rapidly changing environment is creating new responsibilities for all staff, including technicians

Technicians can stay involved in the profession and connected with others after retirement

Denise Giambalvo, director of Member Engagement & Business Strategy at the Washington Health Alliance and recently led a biosimilars initiative for the coalition, discusses biosimilar influence of pricing for biologic drugs, trends to expect in 2024, and why education on biosimilars are important for patients, pharmacists, prescribers, and more

Pharmacists address aspects of patient care that are unique to the focus of the pharmacist, such as financial toxicity and data collection for components of social determinants of health (SDOH).

Cheryl Larson, president and CEO of the Midwest Business Group on Health, discussed the employers’ perspectives on pharmacy benefit manager (PBM) reform efforts and how they can dovetail with the concerns of pharmacies.

It will be interesting to see RSV hospitalization rates over this upcoming season following the rollout of RSV vaccines and monoclonal antibody administration.

Paul Feuerstadt, MD, FACG, AGAF, discusses insights in current treatment practices for CDI at the Peggy Lillis Foundation’s 2023 State of C diff Virtual Town Hall.

Zavegepant (Zavzpret; Pfizer) is the first and only only CGRP receptor antagonist as a nasal spray for the acute treatment of migraine in adults with and without aura approved by the FDA.

Eligible individuals with opioid use disorder using fentanyl received a single 4 mg dose of transmucosal buprenorphine followed by the extended-release buprenorphine 300 mg injection after approximately 1 hour.

Free apps can help patients track cravings, monitor triggers, and stay motivated

Christian John Lillis, co-founder and executive director at Peggy Lillis Foundation, discusses the role of the pharmacist in education that advances C diff awareness in the medical community.

Mice with human breast cancer tissue and high levels of the Myc cancer-driving gene who received a vitamin B5-deficient diet had slower tumor growth.

The study authors suggest that future research should instead emphasize event rates and patient-reported outcomes to better evaluate the tolerability and frequency of AEs.

Despite patients and clinicians preferring in-person consultations, most patients reported that clinicians answered all questions and effectively resolved issues during remote consultations.

In the second part of his interview with Pharmacy Times, PharmD, CSP, AAHIVP, a clinical pharmacist and subject matter expert with Shields Health Solutions, discussed pharmacists’ role in HIV education and management.

Improvements were seen in left ventricular ejection fraction, NYHA Functional Class, and Minnesota Living with Heart Failure Questionnaire at 1-year post-dose.

The results suggest that telemedicine could be used to help improve access for other populations that might be stigmatized, beyond hepatitis C virus and opioid use disorder.

Investigators believe that the activation of mast cells drives inflammation and contributes to plaque buildup, causing heart attacks and other damage to the heart.

Artificial intelligence could help detect a trend in medical information for individuals that would help physicians predict an increased risk of sudden cardiac death.

Study investigators found that health care professionals who were assigned male at birth and practiced in the Western region of the United States were more likely to prescribe PrEP to this high-risk population.

Patient sues pharmacy citing communication gaps after prescription was located

The approval makes pembrolizumab the first-line treatment for individuals with this cancer.

The acceptance comes after results from TRANSCEND CLL 004, which is the first trial to demonstrate clinical benefit with a CAR T cell therapy in patients who were previously treated for CLL or SLL.

The approval makes enzalutamide the first and only androgen receptor-signaling inhibitor approved for the treatment of nonmetastatic castration-sensitive prostate cancer with biochemical recurrence at high risk for metastatic.

Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.

Not only is the test significant for identifying HIV and TB, but it can be safer for patients living with HIV due to their suppressed immune systems.